All News

5 January 2009

Phase III Trial Begins for GAMMAGARD LIQUID Plus rHuPH20 in Primary Immunodeficiency PatientsAntibodies

5 January 2009

Genmab Announces Interim Results in Pivotal Study of Zalutumumab in Head and Neck CancerAntibodies

5 January 2009

UCB receives Complete Response Letter from U.S. FDA for use of Cimzia(R) in rheumatoid arthritis patientsAntibodies

23 December 2008

Phase II study shows trifunctional antibody Removab(R) (catumaxomab) well tolerated in treatment of gastric cancerAntibodies

19 December 2008

Amgen Submits Biologics License Application for FDA Approval of Denosumab in Women With Postmenopausal Osteoporosis and in Patients Undergoing Hormone Ablation for Either Prostate or Breast CancerAntibodies

19 December 2008

FDA Issues Complete Response Letter to Centocor fot Ustekinumab Biologis License ApplicationAntibodies

18 December 2008

Phase III Study Showed Rituxan® Decreased The Progression Of Joint Damage In Patients With Early Rheumatoid Arthritis (RA)Antibodies

18 December 2008

Genmab Sells Arzerra Co-Promotion Rights to GlaxoSmithKlineAntibodies

15 December 2008

FibroGen Has Commenced an Open-Label, Phase 1 Clinical Trial of FG-3019, Anti-Connective Tissue Growth Factor (CTGF) Investigational Therapy, in Patients with Pancreatic CancerAntibodies

15 December 2008

Approval of STELARA(TM) in Canada Marks Advancement in Treatment of Moderate to Severe Plaque PsoriasisAntibodies

12 December 2008

Ablynx REports Positive Phase Ib Results for Its Anti-Thrombotic Nanobody(R) ALX-0081Antibodies

11 December 2008

Herceptin given prior to surgery improves the chance of survival without relapse for women with HER2-positive breast cancerAntibodies

11 December 2008

Crucell Announces Excellent Results for Influenza AntibodyAntibodies

10 December 2008

ABLYNX REACHES MILESTONE IN TNF-alpha NANOBODY(R) COLLABORATION AS WYETH PHARMACEUTICALS INITIATES PHASE IAntibodies

10 December 2008

Active Biotech’s Cancer Project ANYARA: Combination with Established Tumor Therapies PromisingAntibodies

10 December 2008

Seattle Genetics Announces Interim Safety Analysis Supports Continuation of Lintuzumab Phase IIb Clinical TrialAntibodies

10 December 2008

XOMA Provides Clinical Plan Update On Diabetes Drug CandidateAntibodies

9 December 2008

Micromet Presents Updated Data on the Phase 1 Trial Studying Blinatumomab (MT103/MEDI-538) in Patients with Advanced Non-Hodgkin’s LymphomaAntibodies

8 December 2008

ImmunoGen, Inc. Announces Favorable IMGN901 Clinical Findings Reported at ASH Annual MeetingAntibodies

8 December 2008

ERBITUX(R) Supplemental Biologics License Application for Advanced Non-Small Cell Lung Cancer Submitted to U.S. Food and Drug AdministrationAntibodies

8 December 2008

ImmunoGen, Inc. Announces Genentech’s Fifth TAP Technology LicenseAntibodies

8 December 2008

Medarex Announces Enhanced Activity Data with Second Generation Anti-CD30 Antibody for Malignant LymphomaAntibodies

8 December 2008

Long-term Follow Up Interim Data Show Nplate(TM) Increased and Sustained Platelet Counts in Adult Chronic ITP PatientsAntibodies

8 December 2008

Ablynx Expands Its Anti-Thrombotic Portfolio and Announces Initiation of a Phase I Study for ALX-0681Antibodies

8 December 2008

Immunomedics Reports Preliminary Results of Milatuzumab In Multiple Myeloma StudyAntibodies

8 December 2008

Immunomedics Reports Initial Results From Phase I/II Study of Veltuzumab in Immune Thrombocytopenic PurpuraAntibodies

8 December 2008

BioWa Licenses POTELLIGENT(R) Technology to GlaxoSmithKline for Use in Antibody Development and CommercializationAntibodies

8 December 2008

Alexion Reports Positive Results from AEGIS Registration Study of Soliris in Japanese Patients With PNHAntibodies

8 December 2008

Arzerra(TM) (ofatumumab) Demonstrates High Response Rates in Patients With Fludarabine Refractory Chronic Lymphocytic Leukemia (CLL)Antibodies

8 December 2008

Zevalin Consolidation in Patients With Complete Remission After Induction Therapy Results in Durable Remission of More Than 67 MonthsAntibodies

News Channels

Newsletter

La Merie Biologics

La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.

Newsletter La Merie Biologics

Newsletter

New Product Alert

La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.

Newsletter new product alert

Featured reports

Claudin 6: A target opportunity to develop effector-enhanced drug modalities

B7-H4 Targeted Antibody Therapy Pipeline Review

Folate Receptor alpha (FRα) Targeted Therapy Pipeline Review

CAR-M Industry Landscape Analysis: Chimeric Antigen Receptor-Macrophage (CAR-M) Stakeholders, Technologies, Pipeline, Partnering and Financing

CD40 Agonists & CD40/L Antagonists Pipeline Review

TSLP Pipeline Review

Cadherin 17: A target opportunity to develop effector-enhanced drug modalities

TCR Engineered T-Cell Therapy 2018: an industry analysis of technologies, pipelines, stakeholders & deals

CCR8-Targeted Antibody Immunotherapy Pipeline Review

TL1A Inhibitor Pipeline Review